PeptideStack
5.2kquestions
20kanswers
220users

How do I read an impurity table on a tirzepatide certificate against the 97.6% headline?

Asked 30 Dec 2024Modified 16 months agoViewed 24k times
38

For reference: tirzepatide · 97.6%.

I would like the arithmetic checked rather than the conclusion asserted.

I have deliberately not used an online calculator because I want to be able to check the result.

What is the general form of this calculation?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
shareeditfollowflag
DZ
askedDr_Marek_Zielinski39k3830 Dec 2024

3 Answers

Sorted by votes
8

Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

The part that matters: integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
TQ
answeredtriple_agonist_q37k3813 Apr 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
6

In practice, the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
NK
answerednadia_kowalczyk14k172 Apr 2025
2

Specifically, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

The part that matters: the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 7 Apr 2025 by elke_brunner — removed a claim I could not source

shareimprove this answerflag
EB
answeredelke_brunner14k1822 Mar 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.